{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T03:16:40Z","timestamp":1770088600597,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In prostate cancer (PCa) patients treated with radical prostatectomy (RP), multidisciplinary tumor boards (MDT) issue recommendations to undergo adjuvant (aRT) or salvage radiotherapy (sRT). However, reliable data regarding the adherence rate to MDT recommendations and subsequently its impact on oncological outcomes are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively identified patients treated with RP within a certified prostate cancer center between 2012 and 2016, receiving an MDT recommendation to undergo adjuvant or salvage radiotherapy following RP due to adverse pathological features (non-organ confined disease, positive surgical margin, positive lymph node). Patients with a follow-up\u2009&lt;\u20093 years were excluded. Among patients recommended to undergo aRT, adherence rate was calculated. Patients adherent vs. non-adherent to aRT recommendation were compared regarding biochemical recurrence (BCR), PSA failure following aRT or sRT, and cancer-specific (CSS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 802 patients, 408 (51.5%) were recommended to undergo aRT. Among those, 121 (30%) received aRT, whereas 287 (70%) were non-adherent to aRT-MDT recommendation. In multivariable logistic regression models, age, performance status and presence of adverse pathological features represented statistically significant predictors to undergo aRT. Rates of BCR (40.4 vs. 66.6%) as well as subsequent median time of PSA failure following radiotherapy (83 vs. 42 months) favored patients adherent to aRT recommendations (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). No differences were recorded in CSS and OS analyses regarding adherence to aRT recommendations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Solely a fraction of patients followed the recommendation to undergo aRT. Patients adherent to aRT recommendation demonstrated lower rates of subsequent PCa recurrences, albeit not (yet) translating into CSS\/OS differences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-025-04620-0","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T16:59:58Z","timestamp":1752253198000},"page":"433-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adherence to post-therapeutic multidisciplinary tumor board recommendation and its influence on oncological outcomes in high-risk prostate cancer patients following radical prostatectomy"],"prefix":"10.1007","volume":"58","author":[{"given":"Benedikt","family":"Hoeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Kwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Baunacke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Herout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Borkowetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"4620_CR1","unstructured":"Cornford P, Tilik D. EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978\u201394\u201392671\u201323\u20133. EAU Guidelines Office, Arnhem, The Netherlands. https:\/\/uroweb.org\/guidelines."},{"issue":"1","key":"4620_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A (2020) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77(1):38\u201352","journal-title":"Eur Urol"},{"issue":"10\u201312","key":"4620_CR3","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1159\/000534486","volume":"107","author":"D Sikic","year":"2023","unstructured":"Sikic D, Fiebig C, Wullich B, Wolff I, Hoschke B, Manseck A et al (2023) Patient benefits of radical prostatectomy in certified prostate cancer centers: comparative results from the multicenter IMPROVE Study. Urol Int 107(10\u201312):949\u2013958","journal-title":"Urol Int"},{"issue":"5","key":"4620_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00345-015-1688-z","volume":"34","author":"C Kowalski","year":"2016","unstructured":"Kowalski C, Ferencz J, Albers P, Fichtner J, Wiegel T, Feick G et al (2016) Quality assessment in prostate cancer centers certified by the German Cancer Society. World J Urol 34(5):665\u2013672","journal-title":"World J Urol"},{"key":"4620_CR5","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2023.0169","author":"J Schmitt","year":"2023","unstructured":"Schmitt J, Klinkhammer-Schalke M, Bierbaum V, Gerken M, Bobeth C, R\u00f6\u00dfler M et al (2023) Initial cancer treatment in certified versus non-certified hospitals. Deutsches \u00c4rzteblatt Int. https:\/\/doi.org\/10.3238\/arztebl.m2023.0169","journal-title":"Deutsches \u00c4rzteblatt Int"},{"issue":"1","key":"4620_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12913-020-4930-3","volume":"20","author":"ML Specchia","year":"2020","unstructured":"Specchia ML, Frisicale EM, Carini E, Di Pilla A, Cappa D, Barbara A et al (2020) The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res 20(1):73","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"4620_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.healthpol.2014.09.006","volume":"119","author":"J Prades","year":"2015","unstructured":"Prades J, Remue E, Van Hoof E, Borras JM (2015) Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy 119(4):464\u2013474","journal-title":"Health Policy"},{"issue":"20","key":"4620_CR8","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1200\/JCO.20.03714","volume":"39","author":"D Tilki","year":"2021","unstructured":"Tilki D, Chen MH, Wu J, Huland H, Graefen M, Wiegel T et al (2021) Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death. JCO 39(20):2284\u20132293","journal-title":"JCO"},{"issue":"10260","key":"4620_CR9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P et al (2020) Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet 396(10260):1422\u20131431","journal-title":"Lancet"},{"issue":"2","key":"4620_CR10","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1016\/j.clgc.2019.09.007","volume":"18","author":"S Knipper","year":"2020","unstructured":"Knipper S, Sadat-Khonsari M, Boehm K, Mandel P, Bud\u00e4us L, Steuber T et al (2020) Impact of adherence to multidisciplinary recommendations for adjuvant treatment in radical prostatectomy patients with high risk of recurrence. Clin Genitourin Cancer 18(2):e112\u2013e121","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"4620_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000536609","volume":"108","author":"S Sigg","year":"2024","unstructured":"Sigg S, Arnold W, Grossmann NC, Baumeister P, Fankhauser CD, Wenzel M et al (2024) Why do men reject adjuvant radiotherapy following radical prostatectomy? A Systematic Survey Urol Int 108(3):211\u2013218","journal-title":"A Systematic Survey Urol Int"},{"key":"4620_CR12","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundationfor Statistical Computing; 2021. http:\/\/www.R-project.com\/."},{"issue":"27","key":"4620_CR13","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","volume":"28","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. JCO 28(27):4120\u20134128","journal-title":"JCO"},{"key":"4620_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13729","author":"S Davies","year":"2022","unstructured":"Davies S, Voutsadakis IA (2022) Adherence to adjuvant hormonal therapy in localised breast cancer. European J Cancer Care. https:\/\/doi.org\/10.1111\/ecc.13729","journal-title":"European J Cancer Care."},{"issue":"6","key":"4620_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1001\/jamaoncol.2018.0126","volume":"4","author":"EL Van Blarigan","year":"2018","unstructured":"Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ et al (2018) Association of survival with adherence to the american cancer society nutrition and physical activity guidelines for cancer survivors after colon cancer diagnosis: the CALGB 89803\/Alliance Trial. JAMA Oncol 4(6):783","journal-title":"JAMA Oncol"},{"issue":"3","key":"4620_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","volume":"181","author":"IM Thompson","year":"2009","unstructured":"Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956\u2013962","journal-title":"J Urol"},{"issue":"9858","key":"4620_CR17","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","volume":"380","author":"M Bolla","year":"2012","unstructured":"Bolla M, Van Poppel H, Tombal B, Vekemans K, Da Pozzo L, De Reijke TM et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380(9858):2018\u20132027","journal-title":"Lancet"},{"issue":"2","key":"4620_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","volume":"66","author":"T Wiegel","year":"2014","unstructured":"Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A et al (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96\u201302\/AUO AP 09\/95 Trial. Eur Urol 66(2):243\u2013250","journal-title":"Eur Urol"},{"issue":"5","key":"4620_CR19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.eururo.2019.07.001","volume":"76","author":"G Hackman","year":"2019","unstructured":"Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T et al (2019) Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol 76(5):586\u2013595","journal-title":"Eur Urol"},{"issue":"10","key":"4620_CR20","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 0803\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 21(10):1331\u20131340","journal-title":"Lancet Oncol"},{"issue":"10","key":"4620_CR21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I, Magn\u00e9 N, Benyoucef A, Supiot S et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 21(10):1341\u20131352","journal-title":"Lancet Oncol"},{"key":"4620_CR22","unstructured":"Wirth M. Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 3.1, Oktober 2014. 2014;345."},{"key":"4620_CR23","unstructured":"Grimm MO. Leitlinienprogramm Onkologie | Prostatakarzinom | Langversion 7.0 | Mai 2024. 2024;345."},{"issue":"20","key":"4620_CR24","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1200\/JCO.21.02800","volume":"40","author":"D Tilki","year":"2022","unstructured":"Tilki D, Chen MH, Wu J, Huland H, Graefen M, D\u2019Amico AV (2022) Adjuvant versus early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer and the risk of death. JCO 40(20):2186\u20132192","journal-title":"JCO"},{"issue":"5","key":"4620_CR25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bju.13679","volume":"119","author":"D Tilki","year":"2017","unstructured":"Tilki D, Preisser F, Tennstedt P, Tober P, Mandel P, Schlomm T et al (2017) Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN 1 prostate cancer treated with radical prostatectomy. BJU Int 119(5):717\u2013723","journal-title":"BJU Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04620-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04620-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04620-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:21:44Z","timestamp":1770042104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04620-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4620"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04620-0","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethic committee of the Technische Universit\u00e4t Dresden (EK53022014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}